Charts

10 Feb, 2024
09 Feb, 2024

News

21 Feb, 2024
Investors eyeing a purchase of Axsome Therapeutics Inc (AXSM) shares, but tentative about paying the going market price of $81.20/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2026 put at the $60 strike, which has a bid at the time of this writing of $7.90..
Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call Transcript February 20, 2024 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-2.08 EPS, expectations were $-1.21. Axsome Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and […]
Q4 2023 Axsome Therapeutics Inc Earnings Call
20 Feb, 2024
AXSM earnings call for the period ending December 31, 2023.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Amgen Inc (AMGN), where a total volume of 16,292 contracts has been traded thus far today, a contract volume which is representative of approximately 1.6 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 47.6% of AMGN's average daily trading volume over the past month, of 3.4 million shares..
Axsome Therapeutics Inc(NASDAQ:AXSM) reported fourth-quarter 2023 revenues of $71.53 million, up from $24.37 million a year ago, ...
Axsome reported strong fourth-quarter sales Tuesday, but AXSM stock tumbled on a setback for the company's Alzheimer's agitation treatment.
Net Product Revenue Soars as Company Advances CNS Disorder Pipeline
Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million, respectively, representing year-over-year growth of 193% and 309% Auvelity 4Q and full year 2023 net product sales of $49.0 million and $130.1 million, respectively, during the first full year of launch Sunosi 4Q and full year 2023 net product revenue of $22.5 million and $74.8 million, respectively, representing 17% and 67% year-over-year growth NDA submission for AXS-14 in fibromyalgia and NDA resubmission for
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue ...
19 Feb, 2024
Axsome Therapeutics (NASDAQ:AXSM) is set to give its latest quarterly earnings report on Tuesday, 2024-02-20. Here's what investors need ...
16 Feb, 2024
13 Feb, 2024
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
12 Feb, 2024
With the business potentially at an important milestone, we thought we'd take a closer look at Axsome Therapeutics...
08 Feb, 2024
These market-beating stocks could be just getting started.
06 Feb, 2024
UBSinitiated coverage onAxsome Therapeutics Inc(NASDAQ:AXSM), a biotech firm focused on developing and marketing ...
In the last three months, 8 analysts have published ratings on Axsome Therapeutics (NASDAQ:AXSM), offering a diverse range of ...
26 Jan, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK). "I think that ...
25 Jan, 2024
RBC Capitalinitiated coverage onAxsome Therapeutics Inc(NASDAQ:AXSM), citing that its near-term revenue growth and ...
23 Jan, 2024
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year of 2023 on Tuesday, Feb. 20, 2024, before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 a.m. Eastern Time on Feb. 20, 2024, to discuss
22 Jan, 2024
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Nasdaq Pharmaceuticals ETF (FTXH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $30.61 per unit.
16 Jan, 2024
Across the recent three months, 6 analysts have shared their insights on Axsome Therapeutics (NASDAQ:AXSM), expressing a variety of ...
08 Jan, 2024
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Nkarta Inc (NKTX), where a total of 5,498 contracts have traded so far, representing approximately 549,800 underlying shares. That amounts to about 43.3% of NKTX's average daily trading volume over the past month of 1.3 million shares..
05 Jan, 2024
Axsome (AXSM) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also provides regulatory updates on its pipeline candidates. Shares rise.
04 Jan, 2024
Preliminary total 4Q and full year 2023 net product revenue of $71 million and $204 million, respectively Auvelity preliminary 4Q and full year 2023 net product sales of $49 million and $130 million, respectively Sunosi preliminary 4Q and full year 2023 net product revenue of $22 million and $74 million, respectively 2024 anticipated regulatory milestones include NDA submission for AXS-14 in fibromyalgia and NDA resubmission for AXS-07 in migraine 2024 anticipated clinical trial readouts include
03 Jan, 2024
Is it too late to invest in these fast-growing stocks?
02 Jan, 2024
The types of innovative drugs these companies develop are always in high demand.
Buying shares in the best businesses can build meaningful wealth for you and your family. And highest quality companies...
01 Jan, 2024
Investors could enjoy an especially happy new year with these great stocks.
28 Dec, 2023
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Las Vegas Sands Corp (LVS), where a total of 36,179 contracts have traded so far, representing approximately 3.6 million underlying shares. That amounts to about 47.7% of LVS's average daily trading volume over the past month of 7.6 million shares..
21 Dec, 2023
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $19.12 per unit.
11 Dec, 2023
New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode Data on Auvelity exploring reduction of depressive symptoms regardless of a patient’s interest-activity symptom severity NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (C
10 Dec, 2023
11:56
FinancialContent
These stocks could be just the ticket for investors seeking strong growth.
07 Dec, 2023
NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is hosting a virtual investor event and conference call today from 8 a.m. – 10 a.m. Eastern Time to provide an update on solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) and trace amine-associated receptor 1 (TAAR1) agonist. At the event, invited ph
27 Nov, 2023
In this piece, we will take a look at the 11 best upside stocks to buy right now. If you want to skip our overview of share valuation, then take a look at the 5 Best Upside Stocks To Buy Now. The art of buying shares on the market has always gone hand in hand […]
22 Nov, 2023
Many biotech stocks offer exciting long-term growth prospects.
17 Nov, 2023
Rosen Law Firm announces the reopening of the lead plaintiff appointment process in a class action lawsuit against Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) and certain of its officers. The Class Action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-03925 (LGS), is proposed to be brought on behalf of a Class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Axsome common stock between May 10, 2021 and April 22, 2022, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. Excluded from the Class will be any persons who sold all of the shares acquired during the Class Period prior to April 25, 2022.
11 Nov, 2023
Investors shouldn't have to deliberate for too long about these great stocks.
09 Nov, 2023
Can these promising growth stocks continue rising in value?
07 Nov, 2023
Axsome Therapeutics (NASDAQ:AXSM) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...
06 Nov, 2023
Axsome Therapeutics Inc(NASDAQ: AXSM) reported Q3 revenues of $57.8 million, up 244% Y/Y, beating theconsensus of $54.75 ...
AXSM earnings call for the period ending September 30, 2023.
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on ...
03 Nov, 2023
31 Oct, 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Are you looking to invest in stocks with the potential to 10x? Here are three stocks that can 10x by 2025. The post Riding the Wave: 3 Stocks That Can 10X by 2025 appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The #1 AI Investment Might Be This Company You’ve Never Heard Of The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
30 Oct, 2023
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..
27 Oct, 2023
Now, you can scoop up these future growth winners for a bargain.
23 Oct, 2023
Investors in Axsome Therapeutics Inc (AXSM) saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AXSM options chain for the new November 17th contracts and identified one put and one call contract of particular interest.
You can start with a small investment and win big over time.
20 Oct, 2023
Investors in Axsome Therapeutics Inc (AXSM) saw new options begin trading this week, for the January 2025 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 455 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
19 Oct, 2023
11:21
FinancialContent
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $19.44 per unit.
16 Oct, 2023
03 Oct, 2023
Growth catalysts lie ahead for both of these players.
29 Sep, 2023
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on behalf of long-term stockholders following a class action complaint that was filed against Axsome on May 13, 2022 with a Class Period from December 30, 2019 to April 22, 2022. Our investigation concerns whether the board of directors of Axsome have breached their fiduciary duties to the company.
28 Sep, 2023
Looking back to 92 days ago, Axsome Therapeutics Inc (AXSM) priced a 3,000,000 share secondary stock offering at $75.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..
27 Sep, 2023
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.
25 Sep, 2023
Axsome Therapeutics (NASDAQ:AXSM) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...
20 Sep, 2023
Investors considering a purchase of Axsome Therapeutics Inc (AXSM) stock, but cautious about paying the going market price of $73.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2025 put at the $57.50 strike, which has a bid at the time of this writing of $6.00..
15 Sep, 2023
The best may be yet to come for these companies.
12 Sep, 2023
You can get in early on these potential winners.
30 Aug, 2023
Both stocks have outperformed the broader market in the last 12 months.
24 Aug, 2023
Today's market loser could be tomorrow's market winner.
19 Aug, 2023
There's no guarantee that any stock will deliver 2 times returns. But the chances for these stocks look pretty good.
17 Aug, 2023
In trading on Thursday, shares of Axsome Therapeutics Inc (AXSM) crossed below their 200 day moving average of $69.61, changing hands as low as $69.09 per share. Axsome Therapeutics Inc shares are currently trading down about 1.6% on the day..
04 Aug, 2023
15 May, 2023
17:54
Seeking Alpha

Related Articles